Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

Global Intelligent Asthma Monitoring Devices Market is valued at approximately USD 282.48 million in 2022 and is anticipated to grow with a healthy growth rate of more than 25.1% over the forecast ...

GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

United Health Group’s pharmacy benefit manager, Optum Rx, stopped covering Cole Schmidtknecht’s ‘life-changing’ inhaler, suit ...

After some disappointing earlier results for GSK’s new asthma treatment Revlar Ellipta ... The drug, which combines an inhaled corticosteroid (ICS) with a long-acting beta 2 agonist, was ...

Arizona Attorney General Kris Mayes on Thursday sued drug producer GlaxoSmithKline (GSK) for harm done to asthma patients by discontinuing a long-time product.